The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle

NCT ID: NCT00159367

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2006-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We intend to use repetitive magnetic stimulation to the quadriceps muscle to try to improve strength and improve the metabolic function of the muscle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Quadriceps strength is reduced in COPD. Increasing quadriceps strength is one of the goals of pulmonary rehabilitation yet some patients with severe COPD are unable to exercise with sufficient intensity, due to breathlessness, to achieve a true training benefit.

Transcutaneous electrical stimulation of the femoral nerve has been shown to improve quadriceps muscle strength, muscle mass, and performance in patients with severe COPD. Magnetic stimulation may be preferred because it offers the opportunity to train the whole muscle and because it is painless. In this pilot study we are investigating whether repetitive magnetic stimulation camn increase the strength of the quadriceps muscle and whether it confers any change in structure or metabolism of the muscle itself.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Repetitive magnetic stimulation to the quadriceps

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Chronic Obstructive Pulmonary Disease

Exclusion Criteria

Aspirin therapy Cardiac Pacemaker

\-
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Magstim Company, Whitland, Wales

UNKNOWN

Sponsor Role collaborator

Imperial College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Royal brompton Hospital/Imperial College

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael I Polkey, PhD

Role: PRINCIPAL_INVESTIGATOR

Imperial College London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Brompton Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EU QLRT-2001-2285

Identifier Type: -

Identifier Source: secondary_id

RR1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.